Abstract
<b>Background: </b>The role of methylene blue (MB) and hydroxocobalamin (B12) in treating patients with vasoplegic syndromes remains uncertain.<br /> <b>Objective:</b> This systematic review aimed to assess the effects of MB and hydroxocobalamin on patients with vasoplegic syndromes following surgery.<br /> <b>Methods:</b> A systematic search was conducted for articles reporting the use of MB and hydroxocobalamin in vasoplegic syndromes. The databases PubMed, ScienceDirect, Cochrane Library, Springer, Scopus, and medRxiv were systematically searched up to 9 June 2024. Clinical outcomes, hemodynamic outcomes, length of stay (LOS), mortality, and adverse events were extracted from each study.<br /> <b>Results:</b> This review included five studies. The findings from these studies suggested that hydroxocobalamin, with or without MB, effectively reduced vasopressor requirements and improved MAP mainly at 1-hour post-administration. The LOS and mortality did not differ between the two groups. The most common reported side effects for MB include serotonin syndrome. Meanwhile, chromaturia affects the hydroxocobalamin group.<br /> <b>Conclusion: </b>Hydroxocobalamin could lower the need for vasopressors and increase MAP better than MB only. Hydroxocobalamin can also cause temporary chromaturia, which resolves itself. Given the side effects, the choice between MB or hydroxocobalamin for treating vasoplegic syndrome should be based on the patient’s condition. Further studies are required to confirm its findings.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call